The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent

(2012) J. P. VAVALLE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design

(2011) T. J. Povsic et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

(2008) Mark Y. Chan et al.   CIRCULATION

High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism

(2008) A. TRIPODI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

(2008) M. Y. CHAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?

(2008) Séverine Robert et al.   PHARMACOLOGICAL RESEARCH